Clinical Trials

We are evaluating our lead regulatory T cell (Treg) product in clinical trials. This is a critical step in making our hope of finding a cure a reality.

Regulate-RA

We have initiated a Phase 1 study of our lead cell therapy candidate, SBT-77-7101, in patients with rheumatoid arthritis.

For more information Regulate-RA, please visit our clinical trial website.

Learn More

Regulate-HS

We have also initiated a Phase 1 study of 7101 in patients with hidradenitis suppurativa.

For more information about Regulate-HS please visit our clinical trial website.

Learn More

Sonoma Biotherapeutics’ primary mechanism for patient access to investigational products is participation in company-sponsored clinical trials, which are designed to evaluate safety and potential benefit under appropriate regulatory oversight.

Expanded access (compassionate use) requests may be considered on a case-by-case basis, where permitted by law and consistent with applicable regulatory requirements. Expanded access may not be available for all patients or in all circumstances. This policy may be updated as Sonoma’s development programs evolve.